Endostatin in Treating Patients With Advanced Solid Tumors

DISEASE CHARACTERISTICS:

• Histologically proven advanced solid tumor for which no standard curative therapy exists
• Must be amenable to biopsy At least 1 site of measurable disease outside of irradiated field
• No brain metastases by CT or MRI scan

PATIENT CHARACTERISTICS:

• Age: 18 and over
• Performance status: ECOG 0-1
• WBC greater than 3,000/mm3
• Absolute neutrophil count greater than 1,500/mm3
• Platelet count greater than 100,000/mm3
• Hemoglobin greater than 10 g/dL
• Bilirubin less than 1.5 times upper limit of normal (ULN)
• ALT and AST less than 2.0 times ULN
• PT/PTT less than 1.5 times ULN
• Creatinine less than 1.5 mg/dL OR creatinine clearance greater than 60 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No concurrent uncontrolled medical or psychiatric disorder
• No history of bleeding diathesis

PRIOR CONCURRENT THERAPY:

• No concurrent over the counter biologic agents (e.g., shark cartilage)
• At least 3 weeks since prior chemotherapy (6 weeks since nitrosoureas or mitomycin)
• No more than 3 prior chemotherapy regimens for metastatic or recurrent disease (ECOG 1)
• Prior adjuvant chemotherapy for nonmetastatic disease allowed
• Concurrent stable dose of hormone replacement therapy allowed
• At least 3 weeks since prior radiotherapy
• No concurrent radiotherapy
• At least 24 hours since minor surgery (e.g., central venous placement)
• At least 4 weeks since major surgery (e.g., laparotomy, thoracotomy, or craniotomy)
• At least 30 days since other prior investigational agents
• No concurrent herbal remedies
• No concurrent usage of products containing heparin
• No other concurrent anticancer therapy
• Concurrent multivitamins allowed